Trials
3 active
5 in total
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Schizophrenia (2 trials), Bipolar I Disorder
- Main trialPhase 3
- “This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus placebo for the treatment of adult patients with an acute exacerbation of schizophrenia.”In the company’s words, NCT07363577 on ClinicalTrials.gov
Other drugs for Schizophrenia
- CariprazineAbbVie · Phase 3
- EvenamideNewron Pharmaceuticals SPA · Phase 3
- B2227Bostal Drug Delivery Co., Ltd · Phase 2/3
- Brexpiprazole for ER injectionBostal Drug Delivery Co., Ltd · Phase 2/3
- LYBALVIAlkermes, Inc. · Phase 3
- NBI-1117568Neurocrine Biosciences · Phase 3
Coming up3
- Jun 2027Phase 3 trial completes · ClinicalTrials.gov
- Feb 2028Phase 2 trial completes · ClinicalTrials.gov
- Dec 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Jun 2027 | Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia | |
| Phase 3Recruiting | Dec 2028 | 52-week Open Label Safety-Tolerability Study | |
| Phase 2Recruiting | Feb 2028 | Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. | |
| Phase 2Completed | 4 Dec 2024 | Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia | |
| Phase 1Completed | 17 Sep 2021 | Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026